View Financial HealthCizzle Biotechnology Holdings 배당 및 자사주 매입배당 기준 점검 0/6Cizzle Biotechnology Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.4%자사주 매입 수익률총 주주 수익률-0.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 16Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USACizzle Biotechnology Holdings Plc announced the successful laboratory accreditation of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. Working closely with the Company's North American licensing partner Cizzle Bio Inc, the test is now approved for use under Clinical Laboratory Improvement Amendments accreditation at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas, Texas. CLIA approval is regulated by the Centers for Medicare & Medicaid Services and signifies that a laboratory's testing processes and assays meet US federal standards for timely clinical accuracy, reliability, and patient safety and will now enable the test to be made available to licensed U.S. healthcare providers. CLIA compliance is also mandatory for a laboratory to receive Medicare and Medicaid reimbursements. The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a specific protein variant associated with early-stage lung cancer through a simple blood draw. The test is designed to complement LDCT screening and other standard-of-care diagnostic approaches, helping clinicians assess cancer risk, clarify indeterminate findings, and make more informed clinical decisions. Unlike multi-cancer early detection tests that rely on detecting circulating tumor DNA bearing mutation or methylation signals, CIZ1B is designed to detect a stable tumor-associated protein biomarker linked to lung cancer at its earliest stage. This distinct biomarker approach offers important advantages in identifying disease when intervention has the greatest potential to improve outcomes. CIZ1B is offered as a laboratory developed test and is performed exclusively within CLIA-certified laboratory environments, ensuring rigorous quality oversight, analytical control, and compliance with applicable regulatory standards. The validation at OmniHealth confirms the test's analytical performance and operational readiness within a U.S. clinical laboratory environment, supporting scalability, reproducibility, and integration into routine diagnostic workflows. This provides an accredited base to roll the test out across the USA and establishes a strong foundation for growth in other global and home markets. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer. With CLIA accreditation, clinicians and patients will now have access to a scalable test that can help with the detection of lung cancer in its early stages and improve a patient's chance of survival. Achieving CLIA accreditation is necessarily a complex and challenging task and was made possible through working closely with Cizzle's North American Licensing partner, BIO, and its clinical laboratory partner OmniHealth, bringing together the necessary research, development, regulatory, clinical and commercial expertise to deliver a vision to transform lung cancer survival through accurate, low cost, non-invasive early detection at scale. As part of the Company's global licensing strategy, there has been a first focus on the world's largest market in North America to launch its first commercial test. The goal is now to continue to work with the Company's partners to deliver early adoption and scale up. Having established a regulatory approved route to market in the USA, the Company is now also exploring new commercial relationships in the UK, elsewhere in Europe and Asia. This strategy aims to continue to deliver shareholder value through licensing-based royalty payments and potential benefits arising from equity participation in the partner companies where possible.공고 • Jun 12U.S. Patent and Trademark Office Allows Patent Application Covering its Core Methods to Measure CIZ1B Lung Cancer BiomarkerCizzle Biotechnology Holdings plc announced that a patent application covering the Company's core methods to measure the CIZ1B lung cancer biomarker has now been allowed by the U.S. Patent and Trademark Office. This additional patent further enhances the Company's strong patent portfolio, especially in the key market of the USA and follows the grant of a patent in Canada, as announced on 4 February 2026. The USPTO patent, 'Use of a fibrinogen capture agent to detect a CIZ1B variant', concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. for use in North America and the Caribbean, and these new patents strengthen Cizzle Bio Inc.'s position as they prepare to launch the test and establish a robust position for commercialising the Company's innovative and proprietary technology. The CIZ1B biomarker test is the product of work by Professor Dawn Coverley and her research team at the University of York, initially supported by both UK industry and charity sector research grants. The Company's commercial strategy is to licence globally its proprietary test for the CIZ1B biomarker for use in the early detection of lung cancer. Cizzle Biotechnology's patent portfolio and technology know-how is central to securing future licensing and royalty revenue. Developing a strong patent portfolio in North America is intended to enable Cizzle Bio Inc. to establish a leading market position and supports its partnership programme with specialist clinical laboratories and hospitals, enabling market penetration to ensure the test is available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and intends to secure further licensing partnerships with accredited facilities in the UK and Europe, including the NHS. Bringing the CIZ1B biomarker test to market will provide valuable new solutions applicable to the current NHS cancer plan which aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by 2028. The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.공고 • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United KingdomBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.공고 • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.공고 • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.공고 • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom공고 • May 21Cizzle Biotechnology Holdings Plc announced that it has received £0.15 million in fundingCizzle Biotechnology Holdings Plc announced that it has completed a private placement and issued Zero Coupon Convertible loan Notes for aggregate gross proceeds of £150,000 on May 20, 2025. The Note can be converted at any time during its 24 month term into new ordinary shares in the Company at a price of £0.014 per share. The transaction included participation from existing investor Frazer Lang.공고 • Mar 25Cizzle Biotechnology Holdings Plc Announces Board and Committee ChangesCizzle Biotechnology Holdings Plc announced the appointment of Edwin Matthew (Matt) Bower as a Non-Executive Director ("NED") of the Company with immediate effect. Matt Bower is an experienced company executive and adviser with a track record as a director and secretary of private equity backed and listed companies, across a broad range of company and technology related activities. He is engaged as a strategic advisor and mentor to the board of directors of a number of high growth trading and technology companies, and a director of a number of private companies. Matt will sit on both the Company's audit and remuneration committees, alongside the Company's independent Non-Executive Director, John Treacy,replacing Prof Dawn Coverley who recently moved from her role as a NED to Chief Scientific Officer, as announced on 2 January 2025. Matt isa Director of Makabo Limited ("Makabo"), a strategic consultancy and board advisory business.공고 • Jan 03Cizzle Biotechnology Holdings plc Provides Update on Launch of CIZ1B Biomarker AssayCizzle Biotechnology Holdings plc announced successful completion of the technical programme which confirms that the most cost-effective and scalable version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The rigorous quality control programme undertaken has been able to demonstrate equivalence with initial manual laboratory tests and with the BioTechne ProteinSimple capillary Western system. Results have shown sensitivity equivalent to published CIZ1B lung cancer studies, and an ability to correctly identify people with lung cancer with few false negative results. This is another major step in demonstrating that the Company's lung cancer blood test is both cost effective and a commercially scalable global solution to reduce premature cancer deaths and improve survival rates and quality of life for cancer patients.New Risk • Oct 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.07m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€9.07m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.9% increase in shares outstanding).Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jun 05Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United KingdomBoard Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$7.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).공고 • Apr 12Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listing공고 • Mar 27Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct ListingNew Risk • Sep 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£768k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£768k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€8.82m market cap, or US$9.33m). Minor Risk Shareholders have been diluted in the past year (7.1% increase in shares outstanding).공고 • Jun 13Cizzle Biotechnology Holdings Plc announced that it has received £0.35 million in fundingCizzle Biotechnology Holdings Plc announced that it has raised 16,666,667 common shares at a price of £0.021 for the gross proceeds of £0.35 million on June 12, 2023. The transaction will include participation from new and existing investors.공고 • Jun 06Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United KingdomBoard Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Chief Scientific Officer & Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 E7F0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: E7F0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Cizzle Biotechnology Holdings 배당 수익률 vs 시장E7F0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (E7F0)n/a시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.7%업계 평균 (Biotechs)2.3%분석가 예측 (E7F0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 E7F0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 E7F0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 E7F0 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: E7F0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/26 04:49종가2026/07/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cizzle Biotechnology Holdings Plc는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael FosterHardman & Co.Martin HallHardman & Co.
공고 • Jun 16Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USACizzle Biotechnology Holdings Plc announced the successful laboratory accreditation of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. Working closely with the Company's North American licensing partner Cizzle Bio Inc, the test is now approved for use under Clinical Laboratory Improvement Amendments accreditation at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas, Texas. CLIA approval is regulated by the Centers for Medicare & Medicaid Services and signifies that a laboratory's testing processes and assays meet US federal standards for timely clinical accuracy, reliability, and patient safety and will now enable the test to be made available to licensed U.S. healthcare providers. CLIA compliance is also mandatory for a laboratory to receive Medicare and Medicaid reimbursements. The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a specific protein variant associated with early-stage lung cancer through a simple blood draw. The test is designed to complement LDCT screening and other standard-of-care diagnostic approaches, helping clinicians assess cancer risk, clarify indeterminate findings, and make more informed clinical decisions. Unlike multi-cancer early detection tests that rely on detecting circulating tumor DNA bearing mutation or methylation signals, CIZ1B is designed to detect a stable tumor-associated protein biomarker linked to lung cancer at its earliest stage. This distinct biomarker approach offers important advantages in identifying disease when intervention has the greatest potential to improve outcomes. CIZ1B is offered as a laboratory developed test and is performed exclusively within CLIA-certified laboratory environments, ensuring rigorous quality oversight, analytical control, and compliance with applicable regulatory standards. The validation at OmniHealth confirms the test's analytical performance and operational readiness within a U.S. clinical laboratory environment, supporting scalability, reproducibility, and integration into routine diagnostic workflows. This provides an accredited base to roll the test out across the USA and establishes a strong foundation for growth in other global and home markets. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer. With CLIA accreditation, clinicians and patients will now have access to a scalable test that can help with the detection of lung cancer in its early stages and improve a patient's chance of survival. Achieving CLIA accreditation is necessarily a complex and challenging task and was made possible through working closely with Cizzle's North American Licensing partner, BIO, and its clinical laboratory partner OmniHealth, bringing together the necessary research, development, regulatory, clinical and commercial expertise to deliver a vision to transform lung cancer survival through accurate, low cost, non-invasive early detection at scale. As part of the Company's global licensing strategy, there has been a first focus on the world's largest market in North America to launch its first commercial test. The goal is now to continue to work with the Company's partners to deliver early adoption and scale up. Having established a regulatory approved route to market in the USA, the Company is now also exploring new commercial relationships in the UK, elsewhere in Europe and Asia. This strategy aims to continue to deliver shareholder value through licensing-based royalty payments and potential benefits arising from equity participation in the partner companies where possible.
공고 • Jun 12U.S. Patent and Trademark Office Allows Patent Application Covering its Core Methods to Measure CIZ1B Lung Cancer BiomarkerCizzle Biotechnology Holdings plc announced that a patent application covering the Company's core methods to measure the CIZ1B lung cancer biomarker has now been allowed by the U.S. Patent and Trademark Office. This additional patent further enhances the Company's strong patent portfolio, especially in the key market of the USA and follows the grant of a patent in Canada, as announced on 4 February 2026. The USPTO patent, 'Use of a fibrinogen capture agent to detect a CIZ1B variant', concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. for use in North America and the Caribbean, and these new patents strengthen Cizzle Bio Inc.'s position as they prepare to launch the test and establish a robust position for commercialising the Company's innovative and proprietary technology. The CIZ1B biomarker test is the product of work by Professor Dawn Coverley and her research team at the University of York, initially supported by both UK industry and charity sector research grants. The Company's commercial strategy is to licence globally its proprietary test for the CIZ1B biomarker for use in the early detection of lung cancer. Cizzle Biotechnology's patent portfolio and technology know-how is central to securing future licensing and royalty revenue. Developing a strong patent portfolio in North America is intended to enable Cizzle Bio Inc. to establish a leading market position and supports its partnership programme with specialist clinical laboratories and hospitals, enabling market penetration to ensure the test is available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and intends to secure further licensing partnerships with accredited facilities in the UK and Europe, including the NHS. Bringing the CIZ1B biomarker test to market will provide valuable new solutions applicable to the current NHS cancer plan which aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by 2028. The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.
공고 • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United Kingdom
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.
공고 • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.
공고 • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.
공고 • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom
공고 • May 21Cizzle Biotechnology Holdings Plc announced that it has received £0.15 million in fundingCizzle Biotechnology Holdings Plc announced that it has completed a private placement and issued Zero Coupon Convertible loan Notes for aggregate gross proceeds of £150,000 on May 20, 2025. The Note can be converted at any time during its 24 month term into new ordinary shares in the Company at a price of £0.014 per share. The transaction included participation from existing investor Frazer Lang.
공고 • Mar 25Cizzle Biotechnology Holdings Plc Announces Board and Committee ChangesCizzle Biotechnology Holdings Plc announced the appointment of Edwin Matthew (Matt) Bower as a Non-Executive Director ("NED") of the Company with immediate effect. Matt Bower is an experienced company executive and adviser with a track record as a director and secretary of private equity backed and listed companies, across a broad range of company and technology related activities. He is engaged as a strategic advisor and mentor to the board of directors of a number of high growth trading and technology companies, and a director of a number of private companies. Matt will sit on both the Company's audit and remuneration committees, alongside the Company's independent Non-Executive Director, John Treacy,replacing Prof Dawn Coverley who recently moved from her role as a NED to Chief Scientific Officer, as announced on 2 January 2025. Matt isa Director of Makabo Limited ("Makabo"), a strategic consultancy and board advisory business.
공고 • Jan 03Cizzle Biotechnology Holdings plc Provides Update on Launch of CIZ1B Biomarker AssayCizzle Biotechnology Holdings plc announced successful completion of the technical programme which confirms that the most cost-effective and scalable version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The rigorous quality control programme undertaken has been able to demonstrate equivalence with initial manual laboratory tests and with the BioTechne ProteinSimple capillary Western system. Results have shown sensitivity equivalent to published CIZ1B lung cancer studies, and an ability to correctly identify people with lung cancer with few false negative results. This is another major step in demonstrating that the Company's lung cancer blood test is both cost effective and a commercially scalable global solution to reduce premature cancer deaths and improve survival rates and quality of life for cancer patients.
New Risk • Oct 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.07m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€9.07m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.9% increase in shares outstanding).
Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jun 05Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$7.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).
공고 • Apr 12Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listing
공고 • Mar 27Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listing
New Risk • Sep 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£768k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£768k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€8.82m market cap, or US$9.33m). Minor Risk Shareholders have been diluted in the past year (7.1% increase in shares outstanding).
공고 • Jun 13Cizzle Biotechnology Holdings Plc announced that it has received £0.35 million in fundingCizzle Biotechnology Holdings Plc announced that it has raised 16,666,667 common shares at a price of £0.021 for the gross proceeds of £0.35 million on June 12, 2023. The transaction will include participation from new and existing investors.
공고 • Jun 06Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United Kingdom
Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Chief Scientific Officer & Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.